Arvinas Inc. Common Stock (ARVN)

FairStock Score: 33/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a business whose earnings I can understand and predict. Arvinas does not yet offer that. It is a clinical-stage biotech working on targeted protein degraders, and it has lost money in each of the last four years according to the Lynch category data. The reported record is lumpy: in fiscal 2023, revenue was $78.5 million and net loss was $367.3 million; in fiscal 2024, revenue was $263.4 million and net loss $198.9 million; in fiscal 2025, revenue was $262.6 million and net loss $80.8 million. The latest quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $249.7 million and net income of $169.4 million, but that follows fiscal Q1 2026, ended 2026-03-31, with revenue of $15.6 million and a net loss of $57.6 million. Such swings tell me collaboration or milestone payments, not a steady commercial engine, are driving results. The balance sheet looks modestly levered, with debt-to-equity of 0.01, and FairStock's P/B is 0.79. FairStock's Graham Number is $7.10 versus the $6.84 close on 2026-10-13, just a 3.66% margin of safety. But trailing free cash flow is negative $208.8 million, and FairStock's FCF yield is -46.7%. FairStock's Altman Z-score of 1.45 and Piotroski F-score of 5/9 do not signal safety. FairStock's P/E is 26.31, which is not cheap unless the recent profit is durable. I would require proof that ARV-102 and the platform can produce repeatable cash earnings, not one unusual quarter. The stock may be a bargain if clinical and partnering success continues; otherwise, it is a speculative bet on science, not a Graham-style value.

In plain English: Arvinas is a biotechnology company that is testing medicines designed to remove disease-causing proteins. It has not made a yearly profit in recent years and it spends more cash than it brings in, though one recent quarter showed a large gain. At $6.84 a share on 2026-10-13, the price looks roughly near the value suggested by its book value and reported earnings, not clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer